144 related articles for article (PubMed ID: 26517415)
1. Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!
Khanna D; McLaughlin V
Am J Respir Crit Care Med; 2015 Nov; 192(9):1032-3. PubMed ID: 26517415
[No Abstract] [Full Text] [Related]
2. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
3. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
[TBL] [Abstract][Full Text] [Related]
4. Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Mercurio V; Mukherjee M; Tedford RJ; Zamanian RT; Khair RM; Sato T; Minai OA; Torres F; Girgis RE; Chin K; Damico R; Kolb TM; Mathai SC; Hassoun PM
Am J Respir Crit Care Med; 2018 Feb; 197(3):388-391. PubMed ID: 28661697
[No Abstract] [Full Text] [Related]
5. Ambrisentan (Letairis) and tadalafil (Adcirca) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2016 Jan; 58(1485):2-4. PubMed ID: 26714240
[No Abstract] [Full Text] [Related]
6. Effect of ambrisentan on digital ulcers in systemic sclerosis: a case report.
Tomaselli V; D'Ambrosio D; Massarelli L; Roccatello D
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-230-1. PubMed ID: 24774305
[No Abstract] [Full Text] [Related]
7. Pulmonary arterial hypertension in connective tissue diseases.
Goldberg A
Cardiol Rev; 2010; 18(2):85-8. PubMed ID: 20160534
[TBL] [Abstract][Full Text] [Related]
8. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
Abston E; Hon S; Lawrence R; Berman J; Govender P; Farber HW
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):234-238. PubMed ID: 33093789
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy adding tadalafil to existing ambrisentan in patients with pulmonary arterial hypertension.
Hirashiki A; Kondo T; Murohara T
Hypertens Res; 2014 Jun; 37(6):488-9. PubMed ID: 24646649
[No Abstract] [Full Text] [Related]
10. Fibromuscular dysplasia and coronary artery fistula: links to pulmonary hypertension.
Zheng WQ; Kumar S; El-Hajjar M
BMJ Case Rep; 2020 Mar; 13(3):. PubMed ID: 32209581
[No Abstract] [Full Text] [Related]
11. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary hypertension complicating connective tissue disease.
Lynch JP; Belperio JA; Saggar R; Fishbein MC; Saggar R
Semin Respir Crit Care Med; 2013 Oct; 34(5):581-99. PubMed ID: 24037627
[TBL] [Abstract][Full Text] [Related]
13. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.
Saggar R; Khanna D; Shapiro S; Furst DE; Maranian P; Clements P; Abtin F; Dua S; Belperio J; Saggar R
Arthritis Rheum; 2012 Dec; 64(12):4072-7. PubMed ID: 22777623
[TBL] [Abstract][Full Text] [Related]
14. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score.
Frost AE; Hoeper MM; Barberá JA; Vachiery JL; Blair C; Langley J; Rubin LJ
J Heart Lung Transplant; 2018 Dec; 37(12):1410-1417. PubMed ID: 30209017
[TBL] [Abstract][Full Text] [Related]
15. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
[TBL] [Abstract][Full Text] [Related]
16. Biological target proves disappointing in IPF.
Burki TK
Lancet Respir Med; 2013 Jun; 1(4):289. PubMed ID: 24429150
[No Abstract] [Full Text] [Related]
17. Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil.
Cheong FY; Gower AC; Farber HW
Semin Arthritis Rheum; 2017 Feb; 46(4):465-472. PubMed ID: 27499522
[TBL] [Abstract][Full Text] [Related]
18. New drug approved for pulmonary arterial hypertension.
Young D
Am J Health Syst Pharm; 2007 Aug; 64(15):1562. PubMed ID: 17646553
[No Abstract] [Full Text] [Related]
19. Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis.
Baloira Villar A; Pousada Fernández G; Núñez Fernández M; Valverde Pérez D
Arch Bronconeumol; 2015 Apr; 51(4):e19-21. PubMed ID: 24950668
[TBL] [Abstract][Full Text] [Related]
20. Ambrisentan (Letairis) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2007 Oct; 49(1272):87-8. PubMed ID: 17938611
[No Abstract] [Full Text] [Related]
[Next] [New Search]
